key: cord-0813361-6x2jrf8r
authors: N. Agoti, Charles; Githinji, George; S. Mohammed, Khadija; W. Lambisia, Arnold; R. de Laurent, Zaydah; W. Mburu, Maureen; M. Ong’era, Edidah; M. Morobe, John; Otieno, Edward; Abdou Azali, Hamza; Said Abdallah, Kamal; Diarra, Abdoulaye; Ahmed Yahaya, Ali; Borus, Peter; Gumede Moeletsi, Nicksy; Fred Athanasius, Dratibi; Tsofa, Benjamin; Bejon, Philip; James Nokes, D.; Isabella Ochola-Oyier, Lynette
title: Detection of SARS-CoV-2 variant 501Y.V2 in Comoros Islands in January 2021
date: 2021-07-28
journal: Wellcome Open Res
DOI: 10.12688/wellcomeopenres.16889.1
sha: 231d0b915a3d2ab7c550ea92ae0d5d026bc9be53
doc_id: 813361
cord_uid: 6x2jrf8r

Background. Genomic data is key in understanding the spread and evolution of SARS-CoV-2 pandemic and informing the design and evaluation of interventions. However, SARS-CoV-2 genomic data remains scarce across Africa, with no reports yet from the Indian Ocean islands. Methods. We genome sequenced six SARS-CoV-2 positive samples from the first major infection wave in the Union of Comoros in January 2021 and undertook detailed phylogenetic analysis. Results. All the recovered six genomes classified within the 501Y.V2 variant of concern (also known as lineage B.1.351) and appeared to be from 2 sub-clusters with the most recent common ancestor dated 30 (th) Oct-2020 (95% Credibility Interval: 06 (th) Sep-2020 to 10 (th) Dec-2020). Comparison of the Comoros genomes with those of 501Y.V2 variant of concern from other countries deposited into the GISAID database revealed their close association with viruses identified in France and Mayotte (part of the Comoros archipelago and a France, Overseas Department). Conclusions. The recovered genomes, albeit few, confirmed local transmission following probably multiple introductions of the SARS-CoV-2 501Y.V2 variant of concern during the Comoros’s first major COVID-19 wave. These findings demonstrate the importance of genomic surveillance and have implications for ongoing control strategies on the islands.

Although Comoros, an island country in the Indian ocean, detected its first case of SARS-CoV-2 on 30 th April 2020, it experienced its first major SARS-CoV-2 outbreak in January 2021 i.e., 10 months later 1 . By 28 th February 2021, Comoros had 3,571 laboratory-confirmed SARS-CoV-2 infections, 2,748 (76.9%) of which were confirmed after 1 st January 2021.

Genomic surveillance has been key in understanding the introduction, spread, and evolution of SARS-CoV-2 pandemic into countries since its emergence in late 2019 in China and in informing the design and evaluation of interventions [2] [3] [4] . Towards the end of 2020, in widely different geographical locations globally, three SARS-CoV-2 variants of concern (Alpha, Beta, and Gamma) emerged that appeared to be considerably more transmissible and with potential to facilitate immune escape or cause more severe disease than the prior SARS-CoV-2 variants [5] [6] [7] . The three variants possessed several defining amino acid changes, most of them occurring within the immunogenic spike (S) protein 8 . The S protein contains the domain that binds the virus to the human host cell receptor and is a key target for several vaccines 9 . Here, we investigated if the variants of concern had a role in the rising number of SARS-CoV-2 cases in the Union of Comoros in January 2021.

An earlier version of this article can be found on bioRxiv (DOI: https://doi.org/10.1101/2021.04.08.21254321).

The SARS-CoV-2 genomes were generated as part of a regional collaborative COVID-19 public health rapid response. The whole genome sequencing study protocol was reviewed and approved by the Scientific and Ethics Review Committee (SERU), Kenya Medical Research Institute (KEMRI), Kenya (SERU #4035). Individual patient consent was not required by the committee for the use of these samples for sequencing as a part of the public health emergency response.

The samples analysed had been collected between 5 th and 11 th January 2021 in the Union of Comoros, specifically from two islands, Ngazidja and Mohéli (Table 1) . A total of 11 positive nasopharyngeal/oropharyngeal swab samples were sent to KEMRI-Wellcome Trust Programme (KWTRP) in Kilifi, Kenya, for genome analysis. KWTRP is one of the 12 designated WHO-AFRO /Africa-CDC specialized and regional reference laboratories for SARS-CoV-2 sequencing in Africa 10 . Sample size was determined by the sequence available from the public health response.

On receiving the samples on the 16 th and 17 th January 2021, viral RNA was extracted using the QIAamp Viral RNA Mini kit (52906, Qiagen, Hilden, Germany) following the manufacturer's instructions and analysed using the Sansure Biotech Novel Coronavirus (2019-nCoV) Nucleic acid Diagnostic real-time RT-PCR commercial kit (S3102E, Sansure Inc., China) which targets the nucleocapsid (N) and ORF1ab regions. Nine of the 11 samples were confirmed as SARS-CoV-2 positive by both gene targets (cycle threshold (Ct) <38.0). We proceeded to sequence six samples that had a Ct value of ≤ 29.0. Samples with Ct above 29.0 were excluded because we observed in our laboratory that they frequently fail the downstream quality control steps before sequencing due to possession of low viral titres. The RNA was first reverse transcribed using the LunaScript® RT SuperMix Kit (E3010, New England Biolabs Inc., Germany) then amplified using the Q5® Hot Start High-Fidelity 2X Master Mix (NEB M0494; New England Biolabs Inc., Germany) along with the ARTIC nCoV-2019 version 3 primers 11 . The resultant amplicons were taken forward for library preparation and MinION (Mk1B) (Oxford Nanopore Technology, Oxford) sequencing. The six samples were processed alongside 17 other samples from coastal Kenya to make a batch of 23 samples.

The MinION (https://nanoporetech.com/products/minion) sequencing read-outs (fast5 files) were base-called using the Guppy basecaller 4.4.0 fast model and subsequently demultiplexed. Consensus genomes assembled using a SARS-CoV-2 ARTIC Network Bioinformatics pipeline 11 . A threshold of 20x coverage was required for a base to be included in the consensus genome otherwise it was masked to N. We retrieved 75 random Beta variant sequences from the GISAID database (selected by downloading all the Beta variant sequences that were available on 28 th February 2021 and then using an inhouse python script to sub-sample). These data were then aligned with the Union of Comoros genomes (now available on GISAID) using MAFFT v.7.313 (https://mafft.cbrc.jp/alignment/software/). The alignment was manually inspected in SEAVIEW v 4.6.4 (http://doua. prabi.fr/software/seaview) to spot any obvious misalignments. We reconstructed maximum likelihood (ML) phylogeny using IQTREE v.1.6.12 (http://www.iqtree.org/). Branch support was evaluated using 1,000 bootstrap iterations. The presence of a molecular clock signal was inspected in TempEst v1.5.3 (http:// tree.bio.ed.ac.uk/software/tempest/). Linear regression of rootto-tip genetic distances against sampling dates were plotted in R v4.0.2 (https://www.r-project.org/). We inferred time-scaled phylogenies in BEAST V1.10.4 (https://beast.community/) under the HKY+G substitution model with an uncorrelated relaxed molecular clock assumption. BEAST Markov chain Monte Carlo (MCMC) runs were set to run 50 million steps with sampling after every 2,500 steps 12 . The BEAST run output was analysed in Tracer v1.7.1 (http://tree.bio.ed.ac.uk/software/tracer/). Dated maximum clade credibility phylogeny was inferred using TreeAnnotator v1.10.4 (https://beast.community/treeannotator after discarding 10% as burn-in and visualized using FigTree v1.4.4 (http://tree.bio.ed.ac.uk/software/figtree/).

We assembled >80% of the SARS-CoV-2 genome from each of the six sequenced samples ( Table 1 ). The recovered genomes were classified into the lineage B.1.351 using the Pangolin toolkit v2.3.0 13 . The genomes possessed six of the eight Beta variant defining amino acid changes in the S protein (i.e., L18F, D80A, D215G, K417N, D614G, and A701V) plus a known three amino acid deletion at positions 243-245. Two additional defining amino acid changes (E484K and N501K) which were unconfirmed fell within a region that was not sequenced due to PCR amplicon drop-off. Our findings and confirmation of the presence of the SARS-CoV-2 Beta variant in Comoros samples was conveyed to Union of Comoros authorities on the 22 nd January via the WHO-AFRO office to inform public health actions.

The six Union of Comoros sequences differed only at three nucleotide positions: A13192G (1 genome), T23560C (2 genomes), and G27505T (1 genome). Compared to the Wuhan 2019 reference (Accession number: NC_45512.2), the Union of Comoros genomes had 21-22 nucleotide substitutions that translated into 16-17 amino acid changes. A time-scaled MCC phylogenetic tree of these sequences revealed that the Union of Comoros genomes formed a monophyletic group together with genomes from Mayotte (which is part of the Comoros archipelago and a French Overseas department) and France (Figure 1 ). This group diverged into two sub-clusters with the most recent common ancestor dated 30 th Oct-2020 (95%CI: 06 th Sep-2020 to 10 th Dec-2020).

We provide evidence of circulation of the Beta variant during the first major SARS-CoV-2 epidemic peak in the Union of Comoros. The Beta variant was first identified in South Africa and had been reported in 41 countries as of 19 th February 2021. Initial data suggested that this variant exhibits up to 6-fold reduction in neutralization activity by post-vaccination sera or convalescent sera from individuals infected by prior variants 14 . Thus, finding this variant in Union of Comoros is concerning since it has potential to overcome pre-existing immunity derived from natural infection or vaccination.

Comoros is limited by the low number of cases sequenced. As of 28 th February 2021, the number of new cases in the Union of Comoros had considerably declined after peaking in mid-January 1 . Comparison of the Union of Comoros genomes with genomes from across the globe found a close relation with those from the neighbouring Mayotte, a French Overseas Department. Mayotte detected its first case of SARS-CoV-2 on 10th March 2020 and experienced its first major SARS-CoV-2 outbreak from mid-January 2021 to mid-March 2021 thus overlapping with the Union of Comoros outbreak. 721 SARS-CoV-2 genomes were available on GISAID database from Mayotte as of 23 rd April 2021 and the majority (52%) were classified I only have a few minor comments as follows: I noticed that there was no mention of the inclusion of negative controls in the sequencing assays, and how the presence of mapped reads in the negative controls, if any, was addressed. This is particularly relevant given the high similarity between the six samples.

Including the assembly pipeline version, and indicating which tool was used in generating the consensus sequence (nonopolish or medaka) may be useful for others who may be interested in including these data in future analyses ○ In Table 1 , perhaps just 'genome coverage', +/-number of Ns, may be more appropriate than 'genome length'. Is the study design appropriate and is the work technically sound? Yes

Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes

Reference Source

Main Routes of Entry and Genomic Diversity of SARS-CoV-2, Uganda. Emerg Infect Dis

Rapid SARS-CoV-2 wholegenome sequencing and analysis for informed public health decisionmaking in the Netherlands

The emergence of SARS-CoV-2 in Europe and North America

PubMed Abstract | Publisher Full Text | Free Full Text

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein

Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus

A Guide to Emerging SARS-CoV-2 Variants

Structural genetics of circulating variants affecting the SARS-CoV-2 spike/human ACE2 complex

PubMed Abstract | Publisher Full Text | Free Full Text 10. WHO: COVID-19 genome sequencing laboratory network launches in Africa

Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore

Transmission patterns and evolution of respiratory syncytial virus in a community outbreak identified by genomic analysis

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

PubMed Abstract | Publisher Full Text | Free Full Text

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Replication Data for: Detection of SARS-CoV-2 variant 501Y.V2 in Comoros Islands in

We thank the WHO-AFRO and the WHO Kenya and Comoros country offices for facilitating sharing of the positive samples that were sequenced. Further, we thank all laboratories that have shared SARS-CoV-2 sequence data on GISAID.

Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes This is a brief report based on 6 SARS-CoV-2 sequences from the Union of Comoros, which were the only Comoros sequences available in GISAID at the time of publication (July 2021). The samples were from January 2021, during the first major COVID-19 wave. Standard methods were used. Sequences were shown to be of the beta variant of concern and clustered together, similar to sequences from nearby Mayotte and South Africa. Although limited by the small number of sequences and lack of epidemiological data, the report is of local and regional interest as there is little/no molecular epidemiology data from Comoros.There are no major issues.

More relevant details of the setting may help increase understanding of the significance of the findings. For example, case incidence per 100,000 during this wave, incidence in Ngazidja and Mohéli islands, travel restrictions and likely sources of importation, etc.

Is there any further epidemiological data for these 6 cases? e.g. travel history, contact with ○ Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.